Resources from the same session
LBA52 - Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) non-small cell lung cancer (NSCLC)
Presenter: David R Spigel
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
LBA53 - Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
Presenter: Nicolas Girard
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA52 and LBA53
Presenter: Marina Garassino
Session: Proffered paper session: NSCLC metastatic
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: NSCLC metastatic
Resources:
Webcast
LBA54 - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2
Presenter: Sanjay Popat
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
LBA55 - Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
Presenter: Benjamin Besse
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
1253O - Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours
Presenter: Alexander Drilon
Session: Proffered paper session: NSCLC metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA54, LBA55 and 1253O
Presenter: Jürgen Wolf
Session: Proffered paper session: NSCLC metastatic
Resources:
Slides
Webcast